Tutogen Medical, Inc. Announces New and Expanded Tissue Sourcing Agreements
November 14 2007 - 7:30AM
PR Newswire (US)
ALACHUA, Fla., Nov. 14 /PRNewswire-FirstCall/ -- Tutogen Medical,
Inc. (AMEX:TTG), a leading manufacturer of sterile biological
implant products made from human (allograft) and animal (xenograft)
tissue, announced today that it has entered into a tissue supply
agreement with the University of Miami Tissue Bank and has extended
its existing tissue supply agreement with AlloSource, Inc. Under
the terms of these new five-year agreements, the University of
Miami Tissue Bank and AlloSource will provide Tutogen with various
human tissues used in Tutogen dental, spinal and soft tissue repair
product lines. Guy Mayer, president and chief executive officer of
Tutogen Medical, commented, "We are very pleased to partner with
such prestigious and well respected organizations as the University
of Miami Tissue Bank and AlloSource, Inc. We share their commitment
to improving the health and quality of life for our implant
recipients. These new and expanded agreements, along with several
other tissue sourcing agreements recently signed, are significant
in helping to meet our increasing product demand." About Tutogen
Medical, Inc. Tutogen Medical, Inc. manufactures sterile biological
implant products made from human (allograft) and animal (xenograft)
tissue. Tutogen utilizes its proprietary Tutoplast Process(R) of
tissue preservation and viral inactivation to manufacture and
deliver sterile bio-implants used in spinal/trauma, urology,
dental, ophthalmology, and general surgery procedures. The
Company's Tutoplast(R) products are sold and distributed worldwide
by Zimmer Spine and Zimmer Dental, subsidiaries of Zimmer Holdings,
Inc., Davol Inc. subsidiary of C.R. Bard Inc., the Mentor
Corporation (Mentor), Coloplast Corp., IOP, Inc. and through
independent distributors internationally. For more information,
visit the Company's Web site at http://www.tutogen.com/.
Forward-Looking Statement Disclaimer: This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward- looking
statements typically are identified by use of terms such as "may,"
"will," "should," "plan," "expect," "anticipate," "estimate," and
similar words, although some forward-looking statements are
expressed differently. Forward-looking statements are based on
management's current expectations and are subject to certain risks
and uncertainties that could cause actual results to differ
materially from those set forth or implied by forward-looking
statements. These and other risks are identified in the Company's
filings with the Securities and Exchange Commission, including the
Company's Annual Report on Form 10-K for the fiscal year ended
September 30, 2006. All information in this press release is as of
the date hereof, and the Company undertakes no duty to update this
information unless required by law. Contacts: L. Robert Johnston,
Jr. Lytham Partners, LLC Chief Financial Officer Joe Diaz Tutogen
Medical, Inc. Joe Dorame 386-462-0402 Robert Blum 602-889-9700
DATASOURCE: Tutogen Medical, Inc. CONTACT: L. Robert Johnston, Jr.,
Chief Financial Officer of Tutogen Medical, Inc., +1-386-462-0402,
; or Joe Diaz, Joe Dorame, or Robert Blum, all of Lytham Partners,
LLC, +1-602-889-9700, for Tutogen Medical, Inc. Web site:
http://www.tutogen.com/
Copyright
Tutogen Medical (AMEX:TTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tutogen Medical (AMEX:TTG)
Historical Stock Chart
From Sep 2023 to Sep 2024